公开(公告)号：US20060134653A1

公开(公告)日：2006-06-22

申请号：US11105233

申请日：2005-04-13

申请人： Christopher Burgess ,  Theodore Catino ,  Gary Molino ,  Susan Myerow ,  Arunthathi Thiagalingam ,  Marcia Lewis ,  Stephen Thibodeau ,  Lisa Boardman ,  Lawrence Burgart

发明人： Christopher Burgess ,  Theodore Catino ,  Gary Molino ,  Susan Myerow ,  Arunthathi Thiagalingam ,  Marcia Lewis ,  Stephen Thibodeau ,  Lisa Boardman ,  Lawrence Burgart

IPC分类号： C12Q1/68

CPC分类号： G01N33/574 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N33/57419 ,  G01N2500/00 ,  G01N2800/52

摘要： The present invention relates to nucleic acid sequences which are overexpressed in colorectal tumors which display a high level of microsatellite instability (MSI-H) vs. tumors displaying a low level of microsatellite instability (MSS), and can thus be used to identify MSI-H in a patient, and be used further to facilitate patient prognosis, monitor disease progression/regression, identify appropriate treatment regimes, and evaluate the efficacy of treatment.

摘要翻译： 本发明涉及在显示高水平的微卫星不稳定性（MSI-H）与显示低水平微卫星不稳定性（MSS）的肿瘤的结直肠肿瘤中过表达的核酸序列，因此可用于鉴定MSI- H，并进一步用于促进患者预后，监测疾病进展/消退，确定适当的治疗方案，并评估治疗的疗效。

公开(公告)号：US20060179496A1

公开(公告)日：2006-08-10

申请号：US11190172

申请日：2005-07-26

申请人： Christopher Burgess ,  Jon Astle ,  Eddie Carroll ,  Theodore Catino ,  Poornima Dwivedi ,  Gary Molino ,  Arunthathi Thiagalingam ,  Marcia Lewis ,  Stephen Thibodeau ,  Lawrence Burgart ,  Lisa Boardman

发明人： Christopher Burgess ,  Jon Astle ,  Eddie Carroll ,  Theodore Catino ,  Poornima Dwivedi ,  Gary Molino ,  Arunthathi Thiagalingam ,  Marcia Lewis ,  Stephen Thibodeau ,  Lawrence Burgart ,  Lisa Boardman

IPC分类号： A01K67/027 ,  C07K14/82 ,  C12Q1/68 ,  C07H21/04 ,  C12P21/06

CPC分类号： G01N33/6893 ,  A01K2217/05 ,  A61K38/00 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57419 ,  G01N2500/00

摘要： This invention relates to novel nucleic acid sequences which are differentially expressed in cancer cells. The invention also relates to proteins and peptides encoded by the sequences, to diagnostic assays and therapeutic agents based on the sequences and proteins, and to probes, antisense constructs, and antibodies derived from the sequences and proteins or peptides. The subject nucleic acids have been found to be differentially expressed by tumor cells, particularly in colon cancer tissue.

摘要翻译： 本发明涉及在癌细胞中差异表达的新型核酸序列。 本发明还涉及由序列编码的蛋白质和肽，基于序列和蛋白质的诊断测定和治疗剂，以及衍生自序列和蛋白质或肽的探针，反义构建体和抗体。 已经发现目标核酸被肿瘤细胞差异表达，特别是在结肠癌组织中。

公开(公告)号：US20060188889A1

公开(公告)日：2006-08-24

申请号：US10700439

申请日：2003-11-04

申请人： Christopher Burgess ,  Susan Myerow ,  Arunthathi Thiagalingam ,  Peter Maimonis ,  Gary Molino ,  Lawrence Burgart ,  Lisa Boardman ,  Stephen Thibodeau ,  Marcia Lewis

发明人： Christopher Burgess ,  Susan Myerow ,  Arunthathi Thiagalingam ,  Peter Maimonis ,  Gary Molino ,  Lawrence Burgart ,  Lisa Boardman ,  Stephen Thibodeau ,  Marcia Lewis

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136

摘要： The present invention relates to novel marker sequences that are differentially expressed in cancer cells or tissue of a subject with cancerous conditions. The present invention also relates to assays for diagnosis, prognosis, staging, monitoring, therapeutic treatment, and marker sequence related agents including probes, primers, antibodies, and therapeutic compositions.

摘要翻译： 本发明涉及在具有癌症病症的受试者的癌细胞或组织中差异表达的新型标记序列。 本发明还涉及用于诊断，预后，分期，监测，治疗性治疗和包括探针，引物，抗体和治疗组合物的标记序列相关试剂的测定。

公开(公告)号：US20080233585A1

公开(公告)日：2008-09-25

申请号：US12047358

申请日：2008-03-13

申请人： Christopher Burgess ,  Susan Myerow ,  Arunthathi Thiagalingam ,  Peter Maimonis ,  Gary Molino ,  Lawrence Burgart ,  Lisa Allyn Boardman ,  Stephen Thibodeau ,  Marcia Lewis

发明人： Christopher Burgess ,  Susan Myerow ,  Arunthathi Thiagalingam ,  Peter Maimonis ,  Gary Molino ,  Lawrence Burgart ,  Lisa Allyn Boardman ,  Stephen Thibodeau ,  Marcia Lewis

IPC分类号： C12Q1/68 ,  C07K16/18 ,  G01N33/53

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136

摘要： The present invention relates to novel marker sequences that are differentially expressed in cancer cells or tissue of a subject with cancerous conditions. The present invention also relates to assays for diagnosis, prognosis, staging, monitoring, therapeutic treatment, and marker sequence related agents including probes, primers, antibodies, and therapeutic compositions.

摘要翻译： 本发明涉及在具有癌症病症的受试者的癌细胞或组织中差异表达的新型标记序列。 本发明还涉及用于诊断，预后，分期，监测，治疗性治疗和包括探针，引物，抗体和治疗组合物的标记序列相关试剂的测定。

公开(公告)号：US08808997B2

公开(公告)日：2014-08-19

申请号：US13005031

申请日：2011-01-12

申请人： Charles Birse ,  Marcia Lewis ,  Steve Ruben ,  Mehdi Mesri

发明人： Charles Birse ,  Marcia Lewis ,  Steve Ruben ,  Mehdi Mesri

IPC分类号： G01N33/53

CPC分类号： G01N33/57423 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57488 ,  G01N33/57492 ,  G01N2333/8114 ,  G01N2333/96486 ,  G01N2800/56

摘要： Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.

摘要翻译： 提供了使用肺癌标志物（LCM）评估（例如诊断），治疗和预防疾病，特别是癌症和特定肺癌的方法和组合物。 为这些和其他用途提供了单个LCM和包含多个LCM的面板。 还提供了用于确定或预测治疗的有效性或使用LCM选择治疗的方法和组合物。 还提供了使用LCM调节细胞功能的方法和组合物。 还提供了调节LCM的组合物（例如拮抗剂或激动剂），例如抗体，蛋白质，小分子化合物和核酸试剂（例如RNAi和反义剂），以及其药物组合物。 还提供了筛选调节LCM的试剂的方法以及通过这些筛选方法鉴定的试剂。

公开(公告)号：US07892760B2

公开(公告)日：2011-02-22

申请号：US12273994

申请日：2008-11-19

申请人： Charles Birse ,  Marcia Lewis ,  Steve Ruben ,  Mehdi Mesri

发明人： Charles Birse ,  Marcia Lewis ,  Steve Ruben ,  Mehdi Mesri

IPC分类号： G01N33/53

CPC分类号： G01N33/57423 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57488 ,  G01N33/57492 ,  G01N2333/8114 ,  G01N2333/96486 ,  G01N2800/56

摘要： Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.

摘要翻译： 提供了使用肺癌标志物（LCM）评估（例如诊断），治疗和预防疾病，特别是癌症和特定肺癌的方法和组合物。 为这些和其他用途提供了单个LCM和包含多个LCM的面板。 还提供了用于确定或预测治疗的有效性或使用LCM选择治疗的方法和组合物。 还提供了使用LCM调节细胞功能的方法和组合物。 还提供了调节LCM的组合物（例如拮抗剂或激动剂），例如抗体，蛋白质，小分子化合物和核酸试剂（例如RNAi和反义剂）及其药物组合物。 还提供了筛选调节LCM的试剂的方法以及通过这些筛选方法鉴定的试剂。